SCHEMBL2990264

SCHEMBL2990264

COc1cc2[nH]cc(-c3cc4c(Cl)ccnc4[nH]3)c2nc1OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.38
CDK9 P50750 10/20 0.37
CCNT1 O60563 9/20 0.37
CHUK O15111 1/20 0.36
INSR P06213 1/20 0.36
MAPK8 P45983 1/20 0.36
CAMKK2 Q96RR4 1/20 0.36
CDC7 O00311 1/20 0.36
PIM1 P11309 1/20 0.36
DYRK1A Q13627 1/20 0.36
CCNB2 O95067 1/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
CCNB3 Q8WWL7 1/20 0.36
MAPK14 Q16539 1/20 0.35
IGF1R P08069 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2993667 0.85 TBK1 (0.41) CDK9CCNT1CHUKINSRMAPK8
SCHEMBL2984674 0.82 EGFR (0.39) EGFRCDK9CCNT1
SCHEMBL2990593 0.81 TBK1 (0.37) CDK9CCNT1CHUKINSRMAPK8
SCHEMBL2984402 0.79 IGF1R (0.51) CDK9CCNT1CHUKINSRMAPK8
SCHEMBL5541427 0.77 IGF1R (0.41) CDK9CCNT1CHUKINSRMAPK8
SCHEMBL13093827 0.77 PIM1 (0.40) EGFRCDK9CDC7PIM1DYRK1A
SCHEMBL5538584 0.76 CDK9 (0.40) CDK9CCNT1CHUKINSRMAPK8
SCHEMBL1779702 0.76 MAP3K14 (0.52) CDK9CCNT1DYRK1AGSK3AGSK3B
SCHEMBL2989437 0.74 CCNT1 (0.42) CDK9CCNT1CHUKINSRMAPK8
SCHEMBL27714423 0.74 IGF1R (0.38) CDK9CCNT1CHUKINSRMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 US disclosed
CN-101052642-A Novel bis-azaindole derivatives, their preparation and their pharmaceutical use as kinase inhibitors AVENTIS PHARMA SA (FR) 2007-10-10 CN disclosed
EP-1799691-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2007-06-27 EP disclosed
WO-2006037875-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 EGFR 560/4885CDK9 90/4885CCNT1 327/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 EGFR 560/4885CDK9 90/4885CCNT1 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.